SCD and fatty liver disease: The inhibition of Cdk4, the downstream kinase of Cyclin D1, can prevent the development of hepatic steatosis by reducing C/ebpα phosphorylation and its target gene, Fasn, Acc, Scd, Gpat, Dgat1, and Dgat2 (54), which is in line with the effect of LY2835219 (inhibitor for Cyclin D1-Cdk4) in this study.